Feb, 2011 Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI), announced today that it has entered into a licensing agreement granting Neopharm Group (“Neopharm”) the exclusive rights to market and sell VitarosĀ®, Apricus Bio’s treatment for erectile…